Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists
Metadatos
Mostrar el registro completo del ítemEditorial
MDPI
Materia
Duloxetine Major depressive disorder (MDD) Real world data Serotonin and norepinephrine reuptake inhibitors (SNRIs)
Fecha
2023-02-15Referencia bibliográfica
Alvarez-Mon, M.A... [et al.]. Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists. Brain Sci. 2023, 13, 333. [https://doi.org/10.3390/brainsci13020333]
Patrocinador
Comunidad de Madrid P2022/BMD-7321Resumen
Major depressive disorder (MDD) is a complex psychiatric disorder that, presented alone
or with other comorbidities, requires different adjustments of antidepressant treatments. Some
investigations have demonstrated that psychoactive drugs, such as serotonin and norepinephrine
reuptake inhibitors (SNRIs), can exert more effective and faster antidepressant effects than other
common medications used, such as serotonin selective reuptake inhibitors (SSRIs), although these
differences are still controversial. During the last five years, the SNRI duloxetine has shown favorable
results in clinical practice for the treatment of MDD, anxiety, and fibromyalgia. Through an online selfcompleted
survey, in the present article, we collected information from 163 psychiatrists regarding
the use of duloxetine and its comparison with other psychiatric drugs, concerning psychiatrists’
knowledge and experience, as well as patients’ preferences, symptoms, and well-being. We discussed
and contrasted physicians’ reports and the scientific literature, finding satisfactory concordances,
and finally concluded that there is agreement regarding the use of duloxetine, not only due to its
tolerability and effectiveness but also due to the wide variety of situations in which it can be used
(e.g., somatic symptoms in fibromyalgia, diabetes) as it relieves neuropathic pain as well.